Press releases
-
March 6, 2026
Tris Pharma Announces Positive Debut Data from Phase 3 ALLEVIATE-1 and 2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting
-
February 26, 2026
Tris Pharma to Present Debut Data from Phase 3 ALLEVIATE 1-2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting
-
January 8, 2026
Tris Pharma Announces Acceptance of New Publication Highlighting Promise of Dual NOP-MOP (dual-NMR) Agonists for the Treatment of Moderate-to-Severe Pain
-
August 28, 2025
Tris Pharma Showcases a Novel Mechanism of Dual-NOP/MOP (NMR) Agonism for the Treatment of Moderate-to-Severe Acute Pain and Encores Positive Phase 3 Data at 2025 Annual PAINWeek Meeting in Las Vegas
-
June 12, 2025
Tris Pharma to Debut Positive Results of Intranasal (Snorting) Human Abuse Potential Study of Cebranopadol, an Investigational First-In-Class Oral Dual-NMR Agonist for the Treatment of Moderate-to-Severe Pain, at the 2025 CPDD Annual Meeting
-
May 1, 2025
Tris Pharma to Unveil Positive Phase 3 Results Including a Strong Safety Profile Showcasing the Potential of Cebranopadol, an Investigational First-in-Class Dual-NMR Agonist for the Treatment of Pain, at the 2025 ASRA Annual Meeting
-
March 6, 2025
Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain
-
August 6, 2024
Tris Pharma Presents New Clinical Data Demonstrating Robust Safety and Efficacy of Investigational, First-in-Class Therapy Cebranopadol for Treatment of Pain
